{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T23:42:23Z","timestamp":1792366943410,"version":"4.4.0"},"reference-count":26,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2007,12,20]],"date-time":"2007-12-20T00:00:00Z","timestamp":1198108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2008,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Circulating soluble urokinase plasminogen activator receptor (suPAR) reflects the immune and pro\u2010inflammatory status of the HIV\u2010infected patient. Highly active antiretroviral therapy (HAART) suppresses suPAR. Independent of the immune response to HAART, suPAR remains elevated in some HIV\u2010infected patients, reflecting possibly a low\u2010grade pro\u2010inflammatory state. Low\u2010grade inflammation has been implicated in insulin resistance and other features of dysmetabolism. Accordingly it is hypothesized that circulating suPAR is associated with the metabolic status of HIV\u2010infected patients on HAART. Fasting plasma suPAR was determined in 36 normoglycaemic HIV\u2010infected patients on HAART (n\u2009=\u200918 lipodystrophic, and n\u2009=\u200918 non\u2010lipodystrophic) who had estimated insulin sensitivity (Rd) and non\u2010oxidative glucose disposal (NOGM) by euglycaemic hyperinsulinaemic clamps, indirect calorimetry, and glucose tracer infusion. Five patients had circadian suPAR concentrations measured (24 hr, 20 min\u2010intervals). suPAR and non\u2010HDL\u2010cholesterol were higher and Rd, NOGM, and limb fat were lower in lipodystrophic patients than in non\u2010lipodystrophic patients (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05). suPAR correlated positively with non\u2010HDL\u2010cholesterol and inversely with Rd, NOGM and limb fat (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.005, n\u2009=\u200936). suPAR also correlated positively with leukocyte count and TNF\u2010\u03b1 (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.01, n\u2009=\u200936) but not with IL\u20106. In multiple regression analyses suPAR was a stronger predictor of dysmetabolism than TNF\u2010\u03b1 and IL\u20106. Circadian suPAR did not systematically fluctuate. In conclusion, suPAR may reflect the metabolic status of the HIV\u2010infected patient on HAART, thus linking low\u2010grade inflammation, immune constitution, lipid and glucose metabolism, and fat redistribution. Circadian suPAR concentration appeared stable, suggesting that sampling schedule does not affect measurement. Further studies addressing whether suPAR predicts lipodystrophy and dysmetabolism in HIV\u2010infected patients are warranted. J. Med. Virol. 80:209\u2013216, 2008. \u00a9 2007 Wiley\u2010Liss, Inc.\n                  <\/jats:p>","DOI":"10.1002\/jmv.21114","type":"journal-article","created":{"date-parts":[[2007,12,20]],"date-time":"2007-12-20T12:19:48Z","timestamp":1198153188000},"page":"209-216","source":"Crossref","is-referenced-by-count":120,"title":["Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV\u2010infected patients receiving highly active antiretroviral therapy"],"prefix":"10.1002","volume":"80","author":[{"given":"Ove","family":"Andersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Eugen\u2010Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Kofoed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen B.","family":"Haugaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,12,20]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(03)00201-4"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm977"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1385\/ENDO:23:2-3:177"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1983.55.2.628"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200305230-00010"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00075197-200209000-00015"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041811"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.01835"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(96)90204-8"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-005-1764-9"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00206.2003"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2004.02367.x"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13802-0"},{"key":"e_1_2_1_15_1","first-page":"7126","article-title":"Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy","volume":"60","author":"Mustjoki S","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200012010-00004"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200404010-00002"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000157950.02076.a6"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.1997.0289"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/stem.150398"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/172460080101600402"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-004-0029-2"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.13.4091"},{"key":"e_1_2_1_24_1","first-page":"717","article-title":"Presence of urokinase\u2010type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance","volume":"79","author":"Sier CF","year":"1999","journal-title":"Lab Invest"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000084844"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.2.455"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2004.02.004"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.21114","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.21114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T08:34:37Z","timestamp":1696667677000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.21114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,20]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["10.1002\/jmv.21114"],"URL":"https:\/\/doi.org\/10.1002\/jmv.21114","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,20]]}}}